[HTML][HTML] Application of different types of CRISPR/Cas-based systems in bacteria
Z Liu, H Dong, Y Cui, L Cong, D Zhang - Microbial cell factories, 2020 - Springer
As important genome editing tools, CRISPR/Cas systems, especially those based on type II
Cas9 and type V Cas12a, are widely used in genetic and metabolic engineering of bacteria …
Cas9 and type V Cas12a, are widely used in genetic and metabolic engineering of bacteria …
[HTML][HTML] Genome editing in bacteria: CRISPR-Cas and beyond
RD Arroyo-Olarte, R Bravo Rodriguez, E Morales-Ríos - Microorganisms, 2021 - mdpi.com
Genome editing in bacteria encompasses a wide array of laborious and multi-step methods
such as suicide plasmids. The discovery and applications of clustered regularly interspaced …
such as suicide plasmids. The discovery and applications of clustered regularly interspaced …
Programmed genome editing by a miniature CRISPR-Cas12f nuclease
Z Wu, Y Zhang, H Yu, D Pan, Y Wang, Y Wang… - Nature chemical …, 2021 - nature.com
The RNA-guided CRISPR-associated (Cas) nucleases are versatile tools for genome editing
in various organisms. The large sizes of the commonly used Cas9 and Cas12a nucleases …
in various organisms. The large sizes of the commonly used Cas9 and Cas12a nucleases …
Plant natural flavonoids against multidrug resistant pathogens
M Song, Y Liu, T Li, X Liu, Z Hao, S Ding… - Advanced …, 2021 - Wiley Online Library
The increasing emergence and dissemination of multidrug resistant (MDR) bacterial
pathogens accelerate the desires for new antibiotics. Natural products dominate the …
pathogens accelerate the desires for new antibiotics. Natural products dominate the …
[HTML][HTML] Cas12n nucleases, early evolutionary intermediates of type V CRISPR, comprise a distinct family of miniature genome editors
W Chen, J Ma, Z Wu, Z Wang, H Zhang, W Fu, D Pan… - Molecular cell, 2023 - cell.com
Type V CRISPR-associated systems (Cas) 12 family nucleases are considered to have
evolved from transposon-associated TnpB, and several of these nucleases have been …
evolved from transposon-associated TnpB, and several of these nucleases have been …
[HTML][HTML] Capsule type defines the capability of Klebsiella pneumoniae in evading Kupffer cell capture in the liver
X Huang, X Li, H An, J Wang, M Ding, L Wang… - PLoS …, 2022 - journals.plos.org
Polysaccharide capsule is the main virulence factor of K. pneumoniae, a major pathogen of
bloodstream infections in humans. While more than 80 capsular serotypes have been …
bloodstream infections in humans. While more than 80 capsular serotypes have been …
[HTML][HTML] Klebsiella oxytoca causes colonization resistance against multidrug-resistant K. pneumoniae in the gut via cooperative carbohydrate competition
Gut colonization with multidrug-resistant (MDR) bacteria enhances the risk of bloodstream
infections in susceptible individuals. We demonstrate highly variable degrees of ex vivo …
infections in susceptible individuals. We demonstrate highly variable degrees of ex vivo …
Decoding the microbiome: advances in genetic manipulation for gut bacteria
Studies of the gut microbiota have revealed associations between specific bacterial species
or community compositions with health and disease, yet the causal mechanisms underlying …
or community compositions with health and disease, yet the causal mechanisms underlying …
Occurrence of high levels of cefiderocol resistance in carbapenem-resistant Escherichia coli before its approval in China: a report from China CRE-network
Q Wang, L Jin, S Sun, Y Yin, R Wang, F Chen… - Microbiology …, 2022 - Am Soc Microbiol
Cefiderocol has been approved in the United States and Europe but not in China. We aim to
evaluate carbapenem-resistant Enterobacterales (CRE) susceptibility to cefiderocol to …
evaluate carbapenem-resistant Enterobacterales (CRE) susceptibility to cefiderocol to …
[HTML][HTML] Guide RNA engineering enables efficient CRISPR editing with a miniature Syntrophomonas palmitatica Cas12f1 nuclease
Y Wang, Y Wang, D Pan, H Yu, Y Zhang, W Chen, F Li… - Cell Reports, 2022 - cell.com
Gene therapy is limited by inefficient delivery of large clustered regularly interspaced short
palindromic repeat (CRISPR) effectors, such as Cas9 and Cas12a nucleases. Cas12f …
palindromic repeat (CRISPR) effectors, such as Cas9 and Cas12a nucleases. Cas12f …